Unexpected therapeutic effect: improvement of baseline chronic asthma symptoms, and has not used inhaler in two months, after second vaccine; This is a spontaneous report from a contactable consumer or other non-health care professional (patient) via Pfizer sponsored A 50-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EW0164)), via an unspecified route of administration (at the age of 50-years), administered in Arm Left on 30Apr2021 10:00 as dose 2, single for COVID-19 immunization. Medical history included asthma from 1979 and ongoing, covid-19 from 2020 to an unknown date had Covid last year , pneumonia, had pneumonia in the past and breathing issues from an unknown date and unknown if ongoing. Concomitant medications included acetylsalicylic acid (BREOPRIN) taken for asthma Start: caller states unknown, but then adds it was many years ago and levosalbutamol tartrate (XOPENEX HFA) taken for asthma from 2006 and ongoing. The patient historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EW0150), via an unspecified route of administration (at the age of 50-years), administered in Arm Left on 09Apr2021 10:00 as dose 1, single for COVID-19 immunization. The patient did not received any other vaccinations within four weeks prior to the first administration date of the suspect vaccine. On 01May2021, the patient experienced unexpected therapeutic effect: improvement of baseline chronic asthma symptoms, and has not used inhaler in two months, after second vaccine. She had recieve both doses of the Pfizer Covid 19 vaccine. She stated that she has had chronic asthma all of her life. She had Covid last year. Reclarified later in report as before the Covid vaccines. She had pneumonia in the past and breathing issues and saw no difference in her breathing, after her first vaccine. She had her second dose, and she had no difficulty with her breathing or shortness of breath and stated that maintenance medications for her asthma, and has not used her inhaler in two months, after the second vaccine. She was reporting the positive change after having both vaccines. She reported that after the second vaccine, she was breathing so much better, and had not used her inhaler. She was still doing very well, she does not need her inhaler and is not short of breath. She stated that between her first and second vaccine, she still had her normal baseline chronic asthma symptoms, which included shortness of breath after activity, and was still using her inhaler. She was calling to provide information, and she felt it should be noted because she felt it was significant. She stated that for protection of herself and for others around her and the second reason was that she was in and out of doctors offices with work, and she did not want to go into offices with immunocompromised patients, and wanted to protect them as well. The treatment was not received for the event. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on an unspecified date in 2020 and had Covid last year. The adverse events resulted in emergency room visit or physician office visit. The facility where the vaccination was administered in hospital affiliated clinic. The clinical outcome of the events was reported as recovered on an unspecified date in May2021.